Abstract. Bone is the second most frequent site of metastasis resulting from thyroid cancer. Many studies have investigated clinical features and prognostic factors of distant metastases stemming from thyroid cancer in Western countries. The purpose of this study was to review clinical characteristics of Korean patients with bone metastasis originating from thyroid cancer. Between January 1985 and August 2004, 28 patients with thyroid cancer were diagnosed with bone metastases at the Yonsei Severance Hospital in Seoul, Korea. Their clinical characteristics were analyzed retrospectively. Incidence of bone metastasis from follicular thyroid cancer was 6.8% (9 of 132 patients), and 0.4% (13 of 3,154 patients) from papillary thyroid cancer, with an odds ratio of 17.67 (95% confidence interval; 7.41-42). Twelve patients had no symptoms of bone metastasis. Overall mean number of metastasis sites was 2.6 ± 1.9, and 12 patients had a solitary bone metastasis. Survival rates between the synchronous and metachronous metastasis groups were not significantly different, and the number of metastasis sites did not affect survival. However, the survival of patients that underwent curative treatment was longer than those with palliation (P = 0.0317). In Korea, the overall incidence of bone metastasis resulting from thyroid cancer was less than our expectation. Many patients were asymptomatic, and had a tendency of undergoing less aggressive or palliative treatment, even though the long-term survival of distant metastasis resulting from thyroid cancer with active treatment is relatively good. Further studies of the prognostic factors and effectiveness of various treatments of these patients are needed to enhance survival. DISTANT metastasis in thyroid cancer is well known and develops in 7% to 23% of patients with differentiated thyroid cancer [1] . In anaplastic thyroid cancer, 25% to 50% of patients may have synchronous pulmonary metastases at the time of diagnosis [2], while 20% of patients with sporadic medullary thyroid carcinoma had distant metastases at the time of diagnosis [3] . Bone is the second most common site of metastasis resulting from thyroid cancer after lung. The incidence of bone metastasis varies along with the degree of differentiation and histologic subtypes of thyroid cancer. Follicular thyroid cancer is the most common histologic origin of bone metastasis among well-differentiated thyroid cancer, with incidences ranging from 7% to 28% [4, 5] , but papillary thyroid cancer has been identified as the least likely subtype to cause bone metastases with incidences ranging from 1.4% to 7% in many reports [6] [7] [8] . According to the time interval from thyroid cancer diagnosis to detection of distant metastasis, metastatic thyroid cancer is classified into two types: synchronous metasatsis (SM) and metachronous metastasis (MM). The differences between these two
DISTANT metastasis in thyroid cancer is well known and develops in 7% to 23% of patients with differentiated thyroid cancer [1] . In anaplastic thyroid cancer, 25% to 50% of patients may have synchronous pulmonary metastases at the time of diagnosis [2] , while 20% of patients with sporadic medullary thyroid carcinoma had distant metastases at the time of diagnosis [3] . Bone is the second most common site of metastasis resulting from thyroid cancer after lung. The incidence of bone metastasis varies along with the degree of differentiation and histologic subtypes of thyroid cancer. Follicular thyroid cancer is the most common histologic origin of bone metastasis among well-differentiated thyroid cancer, with incidences ranging from 7% to 28% [4, 5] , but papillary thyroid cancer has been identified as the least likely subtype to cause bone metastases with incidences ranging from 1.4% to 7% in many reports [6] [7] [8] . According to the time interval from thyroid cancer diagnosis to detection of distant metastasis, metastatic thyroid cancer is classified into two types: synchronous metasatsis (SM) and metachronous metastasis (MM). The differences between these two groups seem to be affected by tumor biology and histology [9] . The incidence of synchronous metastasis is 11% in follicular thyroid cancer, and 2% in papillary thyroid cancer [7] . The incidence of MM for follicular and papillary thyroid cancer is 20% and 10% respectively [10, 11] .
There is little data about Korean patients with bone metastasis resulting from thyroid cancer. In this study, we investigated the clinical characteristics, incidences and survival of thyroid cancer patients with bone metastases diagnosed at a single Korean institution.
Materials and Methods

Study population
Among the patients with distantly metastatic thyroid cancer who were treated at the Severance Hospital from January 1985 to August 2004, 28 patients were identified as having bone metastases. A retrospective study was performed with the review of all available medical records including personal charts, surgical reports, pathology reports and radiographies. Patient survival was verified by telephone and medical records. Only concrete data regarding survival was considered. Mean time of follow-up was 5.3 ± 7.8 years from the diagnosis of thyroid cancer, and 2.4 ± 2.6 years from the date of bone metastasis presentation. Sixteen patients (57%) were diagnosed as having thyroid cancer with bone metastasis at the time of initial presentation, and were categorized as the SM group. Twelve patients (43%) had their thyroid cancer recur distantly in bones after the completion of previous treatment of primary lesions, and were categorized as the MM group.
Statistical analysis
Mean values are reported with accompanying standard deviations. Associations between categorical variables were evaluated using a chi-square test or Fisher's exact test. Ages at the diagnosis of thyroid cancer and metastasis were compared using the Mann-Whitney test. Survival curves were plotted with the KaplanMeier method and log-rank test. Statistical analysis was performed using SPSS 11.0 for Windows (Chicago, IL, USA) software. A P value<0.05 was considered significant.
Results
Clinical and pathologic characteristics
Clinical and pathologic features are presented in Table 1 . There were 5 male and 23 female patients. All patients were over 45 years of age except four of them. Mean age at the diagnosis of thyroid cancer was 56 ± 14.7 years, and was not significantly different between the two groups. Incidences of bone metastasis according to histologic subtypes were 6.8% (9 of 132 patients) for follicular thyroid cancer and 0.4% (13 of 3,154 patients) for papillary thyroid cancer. The odds ratio of bone metastasis between the two subtypes was 17.67 (95% CI; 7.41-42.14). In the SM group, 6 patients (37.5%) had symptomatic bone metastases including bone pain and motor weakness, but the others were totally asymptomatic. In three cases, biopsies of the lumbar spine and ribs indicated the origins of these cancers were the thyroid. Bone metastases of two patients (16.6%) from the MM group were asymptomatically diagnosed by regular follow-up tests, at 1 and 3 years, respectively, after surgical removal of the thyroid cancer. Asymptomatic metastases in the SM group were 8.3 times more frequent than those in the MM group (95% CI; 1.34-51.67). Motor weakness, paraplegia and quadriplegia in all 4 patients resulted from spinal cord compression due to vertebral metastases at the cervical or lumbar spine. In the MM group, bone metastases were diagnosed at 2 months to a maximum of 29 years following the diagnosis of thyroid cancer, and a total of 8 patients (66.6%) were diagnosed within 5 years. Thirteen of 28 patients had performed radioactive iodine scan and all had positive uptake of radioactive iodine at metastatic sites (Table 1) .
Regarding the size of primary thyroid cancers, there were no significant differences between SM and MM group. Mean size of tumor was 3.33 ± 1.3 cm ( Table  2) . But there were more metastasized lymph nodes in the MM group than in the SM one (p = 0.018). In the aspect of capsular and vascular invasion, there were no significant differences between the two groups ( Table 2 ).
Site and treatment of bone metastasis
Twelve patients (42.8%) had a solitary bone metastasis, and four patients (14.2%) had more than 5 metastasis sites, while the mean number of sites was 2.6 ± 1.9. Simultaneous presence of metastasis sites other than bone was noticed in 11 patients (39.2%): at the lung in 9 patients, liver in 1 patient and adrenal gland in 1 patient. The specific sites of bone metastasis are listed in Table 3 . The most frequent site was the spine followed by the rib. Ten of 22 patients with well-differentiated thyroid cancer refused or abandoned the curative treatment for bone metastasis (Table 4) .
Survival analyses
The survival curves and rates are described in Fig. 1 . Median patient survival rate of well-differentiated thyroid cancer with bone metastasis was 3 years, ranging from 0 to 11 years, after diagnosis of bone metastasis. Two patients with undifferentiated thyroid cancer showed one and three months of survival time, respectively. Survival rates at more than 3 years after diagnosis of bone metastasis remained stable in both SM and MM groups, and most of the mortality with thyroid cancer occurred within 3 years. Among the patients with well-differentiated thyroid cancer, the median survival time of the MM group was 3 years (range, 2 months to 11 years), and that of the SM group was 2 years (range, 0 to 10 years). Fig. 1B demonstrates that survival from the diagnosis of metastasis is not significantly different between the SM and MM groups. Regardless of the treatment and timing of metastasis, patients with solitary bone metastasis showed a similar survival rate, compared with those with multiple bone metastases, as shown in Fig. 1C . Patients treated aggressively showed prolonged survival, compared with those treated with palliative therapy (Fig. 1D) .
Discussion
Most published studies on bone metastasis resulting from thyroid cancer were focused on well-differentiated Table 3 . thyroid cancer, such as papillary and follicular types. In general, these cancers are some of the most indolent solid neoplasms, with favorable long-term survival [12] . Papillary thyroid cancer shows a 10-year overall survival rate, ranging between 74% and 93%, as compared to follicular thyroid cancer, with a 10-year survival rate of 43% to 94% [13] . For metastatic diseases from well-differentiated thyroid cancer, a 10-year survival was reported as 13% to as high as 61% [7, [14] [15] [16] . Anaplastic thyroid cancer is one of the most aggressive and lethal undifferentiated cancers, and has a median survival of 4 to 5 months from the time of diagnosis [17] . The relative long-term survival rate of welldifferentiated thyroid cancer has aroused many authors' interest in the metastatic subgroup. Lung metastasis is easily and frequently found in routine radiography of the chest during the follow-up process. On the contrary, imaging of bone is not a common examination site for workup, and therefore the effect of bone metastasis on prognosis and survival has not been the focus of several investigations. The relative incidence of papillary thyroid cancer among bone metastases is higher than that of follicular thyroid cancer, as reported by recent studies [18, 19] and in our study as well. Papillary thyroid cancer is responsible for 46.4% of bone metastases, compared with follicular thyroid cancer accounting for 32.1%. This seems to be due to the fact that papillary thyroid cancer constitutes the largest portion of thyroid cancer, approximately 80% to 85% of malignant epithelial thyroid tumors [20] . However, papillary thyroid cancer is less likely to metastasize to bone than follicular thyroid cancer.
Bone metastasis detected at the time of diagnosis of thyroid cancer, SM, was reported to occur in 40% to 75% of patients who initially diagnosed as thyroid cancer [1, 14, 21, 22] , and in 57% in our cases. This SM is a strong predictor of a relatively poor outcome, but the long-term survival is still quite satisfactory [23] . MM is also a poor prognostic factor, as are solid tumors of other organs. Our study analyzed the survival times of the SM and MM groups, without any significant differences between these groups. Although this survival analysis could not be statistically confirmed because of the small number of subjects, Shoup et al. produced a similar result from an investigation with 242 patients [1] . This fact could indicate that there is no predominance of biological aggressiveness between the cancer cell types of these two groups.
Symptoms from metastatic diseases are an important clue in detecting metastasis, but these do not significantly affect survival, compared with asymptomatic bone metastasis [14] . Asymptomatic bone metastasis in the metachronous group can be detected through serial thyroglobulin measurement and regular radioiodine scans, but at the time of initial presentation, asymptomatic disease is difficult to discover. Multisite metastasis is generally considered to be associated with decreased survival, and limited extent of metastatic disease is a favorable factor for survival [7, 15] , although Pittas et al. reported that the survival in patients who had a single bone lesion was not better than in those with multiple bone lesions [14] . Age is considered as a prognostic factor of improved survival [24, 25] , but in our study, age at diagnosis of bone metastasis was not statistically significant, maybe due to the small number of patients less than 45 years old (not described in above results). Early detection could initiate prompt therapy and improve survival. Also noteworthy is that many Korean patients in our study chose a conservative therapy without any further treatment. In our study, the survival of patients treated with only conservative therapy was reported to be significantly shorter than actively treated patients. Because longterm survival is generally possible even in patients with bone metastasis from well-differentiated thyroid cancer, active and optimal treatment must be carried out.
In conclusion, the overall incidence of bone metastasis from thyroid cancer was less than our expectation in Korea. Time at the detection of metastasis from diagnosis of thyroid cancer and the number of metastasis sites was not a prognostic factor for survival. Active treatment for metastastic disease improved survival, and the long-term survival of distant metastasis resulting from thyroid cancer is relatively good. Further investigation is required to establish the true effect of bone metastasis on the survival and prognosis of this specific group of thyroid cancer patients.
